AI clinical trial optimization market seen reaching $2.8B by 2030

The Business Research Company says the AI clinical trial optimization market is expanding as drugmakers and research firms use automation to speed recruitment, monitoring and analysis. The market is projected to grow from $1.57 billion in 2026 to $2.8 billion by 2030, driven by personalized medicine, decentralized trials and rising R&D spending.

Why it matters: - AI is moving deeper into clinical research as pharmaceutical and biotechnology companies look to cut trial costs, speed enrollment and improve trial success rates. - The market’s projected growth signals broader adoption of predictive modeling, real-time monitoring and data-driven trial design. - Personalized therapeutics and more complex drug development are increasing demand for tools that can match patients to studies more precisely.

What happened: - The Business Research Company released its 2026 report on the AI clinical trial optimization market on Sept. 3, 2026. - The report estimates the market at $1.35 billion in 2025 and $1.57 billion in 2026. - The company projects the market will reach $2.8 billion by 2030. - The forecast implies 16.1% CAGR from 2025 to 2026 and 15.7% CAGR through 2030. - A free sample of the report is available. - The full market report is also available.

The details: - AI clinical trial optimization covers planning, recruitment, monitoring, data analysis and trial management. - The technology is intended to improve trial efficiency, accelerate patient enrollment, reduce operating costs and raise data precision. - Growth is tied to the rising complexity and cost of traditional clinical trials. - The report points to stronger global pharmaceutical research activity and expanding use of contract research organizations. - Stricter regulatory requirements around data accuracy are also supporting demand. - The report says growth through 2030 will be driven by AI-based predictive trial modeling, decentralized and hybrid trial designs, personalized medicine, targeted treatments and digital health infrastructure. - Real-time patient monitoring is one part of that digital infrastructure. - Increased biopharma R&D investment is expected to support more innovation in the sector.

Between the lines: - Personalized medicine is becoming a major commercial driver because more therapies are designed around genetic and clinical profiles rather than one-size-fits-all treatment. - The need for AI-based patient stratification tools is rising as chronic and genetic diseases create more pressure for targeted clinical trials. - A February 2024 update from the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - That total included seven oncology treatments and three therapies for other conditions. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

What's next: - Drugmakers, biotech firms and research organizations are likely to keep adding AI tools as decentralized and hybrid trial models expand. - The report suggests future gains will depend on deeper use of predictive modeling, patient monitoring and trial optimization software. - Asia-Pacific could take a larger share if current growth trends hold.

The bottom line: - AI clinical trial optimization is shifting from a niche tool to a core part of drug development, and the market is on track for sustained double-digit growth through 2030.